logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
T

Toby A. Eyre

Oxford University Hospitals NHS Trust
H指数:39
被引数:5,739

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Coronavirus disease 2019 (COVID-19) risk and evolving treatment patterns in follicular lymphoma during the pandemic: Insights from the PETReA trial

2019冠状病毒病（COVID-19）大流行期间滤泡性淋巴瘤的风险及治疗模式的演变：PETReA试验的启示

British Journal of Haematology
IF3.8
2026-08-210
PRE
S. Williams; Y. J. Lim; R. Cooper; C. Gamble; H. Short; A. Arumainathan; T. A. Eyre; P. McKay; M. Young; M. Bishton; S. Gatto; M. Macheta; A. Zhelyazkova; E. Heartin; F. Miall; V. Warbey; S. Opat; A. Johnston; J. Trotman; K. Linton; A. Pettitt
Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

固定疗程的pirtobrutinib联合venetoclax–rituximab与venetoclax–rituximab治疗既往接受过治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者（BRUIN CLL-322）：一项开放标签、多中心、随机对照、III期临床试验

The Lancet
IF88.5
2026-07-090
OAAI
Matthew S Davids; Toby A Eyre; Jennifer A Woyach; Lindsey E Roeker; Alessandra Ferrajoli; Yucai Wang; Constantine S Tam; Wojciech Jurczak; Pier Luigi Zinzani; Martin Šimkovič; Jian-Yong Li; Francesc Bosch; Damien Roos-Weil; Paula Cramer; Anders Osterborg; Prioty Islam; Ryan Jacobs; Alan Skarbnik; Seema A Bhat; Suhyun Kang
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study

阿卡巴鲁替尼单药治疗作为CLL的一线治疗：真实世界EPIC研究的3年随访

Blood Advances
IF7.1
2026-05-020
OAAI
Toby A. Eyre; Nicolas Martinez-Calle; Shankara Paneesha; Mohsen Norouzi; David Tucker; Harriet Walter; Alison Boden; Mari Kilner; Neil Phillips; Piers EM Patten; Nimish Shah; Meghna Ruparelia; Sharon Oddy; Tan Tsawayo; Francesco Forconi; Helen Wardle; Tobore Gbemre; Chris Gregory; Lucy Cook; David Allsup
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial

帕尔托 Brutinib 在复发或难治性华氏巨球蛋白血症患者中的安全性和活性：开放标签、多中心、I/II 期 BRUIN 试验的 5 年随访

The Lancet Haematology
IF0
2026-04-300
PRE
M Lia Palomba; Manish R Patel; Toby A Eyre; Wojciech Jurczak; David Lewis; Thomas Gastinne; Shuo Ma; Jonathon B Cohen; Krish Patel; Jennifer R Brown; Lydia Scarfò; Talha Munir; Ewa Lech-Maranda; Marc S Hoffmann; Chaitra S Ujjani; Bita Fakhri; Michael L Wang; Koji Izutsu; Hirokazu Nagai; Constantine S Tam
EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma

EHA–EU MCL网络关于套细胞淋巴瘤诊断与治疗指南

HemaSphere
IF14.6
2025-10-220
OAAI
Mats Jerkeman; Igor Aurer; Elias Campo; Chan Y. Cheah; Jonathan Clark; Jeanette Doorduijn; Toby A. Eyre; Martin Fehr; Eva Giné; Maria Gomes da Silva; Pavel Klener; Marco Ladetto; Vincent Ribrag; Ofer Shpilberg; Jan Walewski; Martin Dreyling; the EHA Guidelines Committee and the European MCL Network
Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

Pirtobrutinib对复发/难治性慢性淋巴细胞白血病的反应和耐药性的基因组决定因素

Blood
IF23.1
2025-10-100
OAAI
Jennifer R. Brown; Bastien Nguyen; Sai Prasad Desikan; Helen Won; Shady I. Tantawy; Samuel C. McNeely; Narasimha Marella; Hetal S. Randeria; Lauren M. Hanson; Andrew Parker; Salomé Calado Botelho; Jennifer A. Woyach; Krish Patel; Constantine S. Tam; Toby A. Eyre; Chan Y. Cheah; Nirav N. Shah; Paolo Ghia; Wojciech Jurczak; Minna Balbas; Binoj Nair; Paolo Abada; Chunxiao Wang; Denise Wang; Lindsey E. Roeker; Varsha Gandhi; William G. Wierda
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial

伊布替尼和利妥昔单抗对比免疫化疗用于初治套细胞淋巴瘤患者的随机、开放标签、II/III期优效性试验（ENRICH）

The Lancet
IF97.3
2025-10-030
OAAI
David J Lewis; Mats Jerkeman; Lexy Sorrell; David Wright; Ingrid Glimelius; Christian B Poulsen; Annika Pasanen; Andrew Rawstron; Karin F Wader; Nick Morley; Catherine Burton; Andrew J Davies; Ingemar Lagerlöf; Surita Dalal; Ruth De Tute; Chris McNamara; Nicola Crosbie; Helle Erbs Toldbod; Jeanette Sanders; Victoria Allgar; Sree Aroori; Mark Warner; Claire Scully; Brian Wainman; Jacob Haaber Christensen; Jon Riise; Kristina Sonnevi; Mark J Bishton; Toby A Eyre; Simon Rule
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病后基于维尼托克的治疗效果: 一项国际真实世界研究

AMERICAN JOURNAL OF HEMATOLOGY
IF9.9
2024-12-190
OAAI
Ghosh, Nilanjan; Eyre, Toby A.; Brown, Jennifer R.; Lamanna, Nicole; Manzoor, Beenish S.; Coombs, Catherine C.; Tuncer, Hande H.; Ujjani, Chaitra; Leslie, Lori A.; Roeker, Lindsey E.; Davids, Matthew S.; Rhodes, Joanna M.; Skarbnik, Alan P.; Sinai, Wendy; Fleury, Isabelle; Hill, Brian T.; Martinez-Calle, Nicolas; Barr, Paul M.; Jawaid, Dureshahwar; Emechebe, Nnadozie; Pearson, Laurie; Lansigan, Frederick; Choi, Yun; Jensen, Christopher E.; Fakhri, Bita; Stephens, Deborah M.; Marx, Steven E.; Schuster, Stephen J.; Coyle, Michael; Pivneva, Irina; Watson, Talissa; Guerin, Annie; Shadman, Mazyar
Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial

伊布替尼、维奈克拉联合CD20单克隆抗体为初治MCL患者提供极高的MRD阴性率，OASIS II随机II期试验初步结果。

BLOOD
IF23.1
2024-11-050
PRE
Le Gouill, Steven; de Wilde, Virginie; Eyre, Toby A.; Callanan, Mary B.; Damaj, Gandhi; Claudel, Alexis; Chauchet, Adrien; Houot, Roch; Le Calloch, Ronan; Cacheux, Victoria; Andre, Marc; Morschhauser, Franck; Burroni, Barbara; Lewis, David John; Tessoulin, Benoit; Touzart, Aurore
Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Ibrutinib-Rituximab方案优于Rituximab-化疗方案，用于初治老年套细胞淋巴瘤患者：国际随机对照试验Enrich的研究结果

BLOOD
IF23.1
2024-11-053
PRE
Lewis, David John; Jerkeman, Mats; Sorrell, Lexy; Wright, David; Glimelius, Ingrid; Pasanen, Annika; Christensen, Jacob Haaber; Wader, Karin Fahl; Davies, Andrew J.; Morley, Nick; Mcnamara, Christopher; Poulsen, Christian Bjorn; Riise, Jon; Sonnevi, Kristina; Lagerloef, Ingemar; Burton, Cathy; Dalal, Surita; Rawstron, Andrew; Tute, Ruth M. de; Allgar, Victoria; Aroori, Sree; Warner, Mark; Wainman, Brian; Scully, Claire; Sanders, Jeanette; Niemann, Carsten Utoft; Toldbod, Helle; Crosbie, Nicola; Bishton, Mark J.; Eyre, Toby A.; Rule, Simon
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
HAEMATOLOGICA
IF7.9
2024-10-032
OAAI
Shah, Nirav N.; Wang, Michael; Roeker, Lindsey E.; Patel, Krish; Woyach, Jennifer A.; Wierda, William G.; Ujjani, Chaitra S.; Eyre, Toby A.; Zinzani, Pier Luigi; Alencar, Alvaro J.; Ghia, Paolo; Lamanna, Nicole; Hoffmann, Marc S.; Patel, Manish R.; Flinn, Ian; Gerson, James N.; Ma, Shuo; Coombs, Catherine C.; Cheah, Chan Y.; Lech-Maranda, Ewa; Fakhri, Bita; Kim, Won Seog; Barve, Minal A.; Cohen, Jonathon B.; Jurczak, Wojciech; Munir, Talha; Thompson, Meghan C.; Tsai, Donald E.; Bao, Katherine; Cangemi, Nicholas A.; Kherani, Jennifer F.; Walgren, Richard A.; Han, Hongmei; Ruppert, Amy S.; Brown, Jennifer R.

研究方向

暂未获取到该数据
C
Christopher P. Fox
H 指数:46论文数:333被引数:8,302
G
Graham P. Collins
H 指数:39论文数:398被引数:9,401
A
Anna Schuh
H 指数:60论文数:416被引数:2.2万
K
Kate Cwynarski
H 指数:51论文数:262被引数:8,383
N
Nicolás Martínez‐Calle
H 指数:20论文数:111被引数:1,569
C
Chan Y. Cheah
H 指数:48论文数:467被引数:9,293
P
Paolo Ghia
H 指数:93论文数:1,080被引数:3.7万
N
Nirav N. Shah
H 指数:46论文数:537被引数:9,136
C
Catherine C. Coombs
H 指数:30论文数:225被引数:5,875
J
Jennifer A. Woyach
H 指数:61论文数:608被引数:1.8万